Lexington, Mass., June 12, 2024 — KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing treatments for solid tumors, today announced the first patient dosed in the Phase 1/2 clinical study of KSQ-001EX, a novel edited TIL therapy. KSQ-001EX consists of TIL in which the SOCS1 gene is inactivated by CRISPR/Cas9 gene…

Phase 1/2 clinical study will evaluate the safety, pharmacokinetics, and preliminary efficacy of KSQ-001EX in melanoma, head and neck squamous cell carcinoma, and non-small cell lung cancer  Lexington, Mass., November 29, 2023 — KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing novel treatments for solid tumors, in collaboration with The University…

Collaboration will provide full process development and manufacturing support for KSQ’s lead eTIL programs Lexington, Mass., September 6, 2023 — KSQ Therapeutics, Inc. (“KSQ”), a clinical-stage biotechnology company developing cancer therapies using its proprietary CRISPRomics® discovery platform, and CTMC, a joint venture between National Resilience, Inc. and MD Anderson Cancer Center, announced today…

Lexington, Mass., July 13, 2023 — KSQ Therapeutics, Inc. (“KSQ”), a clinical-stage biotechnology company developing cancer therapies using its proprietary CRISPRomics® discovery platform, announced today it has entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of KSQ-4279. KSQ-4279 is a first-in-class, potent, and selective small…

Expanded collaboration focused on novel target discovery and validation to inform the development of targeted therapies that address resistance mechanisms in patients with cancer Agreement expands the companies’ successful ongoing collaboration focused on discovering natural killer (NK) and T-cell targets Lexington, Mass., May 17, 2023 KSQ Therapeutics, (“KSQ”), a clinical-stage biotechnology…